Stay updated on Ixekizumab for Bullous Pemphigoid Clinical Trial
Sign up to get notified when there's something new on the Ixekizumab for Bullous Pemphigoid Clinical Trial page.

Latest updates to the Ixekizumab for Bullous Pemphigoid Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3. This indicates a small update to the record, typically reflecting editorial or formatting adjustments rather than changes to the study details.SummaryDifference0.1%

- Check16 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2. This indicates a minor update to the page metadata rather than a substantive change to content.SummaryDifference0.1%

- Check30 days agoChange DetectedNew guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added, and a recruitment status note states that the study is no longer looking for participants. The Interventions header has been reformatted to Intervention/Treatment and the page revision footer updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check37 days agoChange DetectedRevision label on the page changed from v3.5.4 to v3.5.5. This indicates a backend release or patch update rather than a modification to study content or visible functionality.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision: v3.5.4 is now displayed on the page, replacing Revision: v3.5.3. This indicates a deployment version update of the site interface rather than a change to study content.SummaryDifference0.1%

- Check80 days agoChange DetectedThe page’s footer revision indicator was updated from v3.5.2 to v3.5.3, reflecting a display/version change rather than any update to the clinical trial study details.SummaryDifference0.1%

Stay in the know with updates to Ixekizumab for Bullous Pemphigoid Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixekizumab for Bullous Pemphigoid Clinical Trial page.